Multiple Myeloma

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.

Whether a patient is refractory to initial treatment dictates the future course of care.

Relapse remains a daunting reality in multiple myeloma, but clinicians have more tools to work with to fight the disease.

Dr Baljević explain some of the limitations physicians can come across with applying randomized clinical trial (RCT) data to MM treatment.

A panel of experts elaborate on the decision support tools that are utilized by physicians to give patients high-value regimens.

Weight and changes in it can indicate implications for cancer risk and cancer diagnosis, according to 2 abstracts being presented at the American Association for Cancer Research Annual Meeting.

The panel discusses the data used to evaluate healthcare resources for MM therapy, as well as economic burden.

Dr Beveridge provides a payer’s perspective on the available regimens for MM treatment.

A new frailty-based outcome prediction model for multiple myeloma (MM) was found to be an easy-to-use tool in clinical practice and produced valid results based on a large real world cohort of patients with a new MM diagnosis, according to a recent study.

Risk stratification is a difficult process for multiple myeloma (MM), and authors concluded that their multi-tiered model may provide a greater risk assessment benefit than standard stratification systems.

Joshua Richter, MD, and Roy Beveridge, MD, explain the role triplet regimens play in MM treatment and how physician decision-making has been impacted since the NCCN guidelines have expanded the list of acceptable first- and second-line treatment options.

Muhamed Baljević, MD, FACP, provides a background of multiple myeloma (MM) within the past five years and the main treatment options.

Researchers found that low levels of vitamin D and the prevalence of peripheral neuropathy were common in patients with multiple myeloma, suggesting that addressing the former could help prevent the latter.

Decorin, a highly conserved, class 1 small leucine-rich repeat proteoglycan expressed in the extracellular matrix, may have a protective effect in a subset of patients with multiple myeloma, investigators concluded.

Investigators concluded that early palliative care may be needed for more patients with multiple myeloma (MM) as pain can manifest in different ways and severity levels depending on disease state, suggesting that a more individualized approach is critical for pain management.

A study showed that patients with multiple myeloma (MM) deal with physical, social, and emotional pain and that physicians did not fully comprehend the extent to which patients experienced pain, suggesting improved communication between parties is warranted.

Health care providers need to foster a greater push for physical activity as a part of survivorship care for patients with multiple myeloma (MM), investigators concluded after finding that only 25% of patients were active.

Access to digital health tools to improve patient outcomes and quality of life are lacking among patients with multiple myeloma (MM) who are elderly, at risk of relapse, or live in rural communities, suggesting more tools and guidelines are needed for these populations.

Two cancer-related micro-RNAs could serve as prognostic biomarkers for multiple myeloma bone disease as lower levels were associated with lower overall survival rates, investigators concluded.

Researchers concluded that incident corneal adverse events in patients with multiple myeloma (MM) carry a low clinical and economic burden compared with total all-cause costs and MM-related per-patient-per-month costs.

Early mortality rates for patients with multiple myeloma (MM) have significantly decreased over the last 20 years; however, more efforts are needed for older patients, who still experience high rates.

A large international real-world analysis revealed the extent to which the COVID-19 pandemic has impacted the global population of patients with multiple myeloma (MM) and the ability for providers to help patients manage the condition.

About half of all patients with multiple myeloma (MM) receiving corticosteroid-based chemotherapy were found to have adrenal insufficiency (AI), while identifying suspicious symptoms of AI may be a key component to its detection in this population.

Research presented at the 2021 American Society of Hematology Annual Meeting and Exposition highlights efforts in screening for multiple myeloma (MM).

Can daratumumab be taken safely as a maintenance therapy? Will quadruplet therapy become more common in the treatment of newly diagnosed multiple myeloma (NDMM)?

Looking toward the future management of patients with multiple myeloma, Rafael Fonseca, MD, shares excitement for novel therapeutic strategies.

Updated results from the GRIFFIN trial in newly diagnosed multiple myeloma, including consideration for frontline 4-drug regimens and depth of response.

Taking into account data from the ASH 2021 annual meeting, Rafael Fonseca, MD, reviews his current approaches to frontline therapy for patients with multiple myeloma.

Rafael Fonseca, MD, reviews data on rescue isatuximab from the ASH 2021 annual meeting and discusses use of best therapies up front.

Insight on the survival benefit seen with frontline daratumumab-based regimens in patients with transplant-ineligible multiple myeloma.